CryoPort (CYRX) agreed to provide its IntegriCell cryopreservation services to support Verismo Therapeutics' KIR-CAR T-cell therapy programs for two product candidates, the companies said Thursday.
No financial terms were disclosed.
Verismo will use IntegriCell to support cryopreservation of the development of SynKIR-110 as a potential treatment for solid tumors and SynKIR-310 in B-cell associated disorders and malignancies, according to the company.
Both product candidates are currently under phase 1 human clinical trials, the companies said.